News

The information below is intended for the healthcare media.

17/6/2026
pharma&’s Rubraca® (rucaparib) Can Delay Time to First and Second Subsequent Treatment by Nearly One Year for Eligible Patients with Newly Diagnosed Advanced Ovarian Cancer

3/6/2026
pharma& to Highlight Subsequent Therapy Data for Rubraca® (rucaparib) in Patients with Advanced Ovarian Cancer at ESMO-GYN Congress 2026

23/4/2026
pharma& Receives Health Canada Approval for Pegasys® Manufacturing Site Variation, Adding Loba biotech for API Production

5/3/2026
pharma& Announces Health Canada has Accepted into Review the Supplement to a New Drug Submission (SNDS) for Pegasys® (peginterferon alfa-2a), for the treatment of polycythaemia vera (PV) and essential thrombocythaemia (ET)

4/3/2026
pharma& Announces Rubraca® (rucaparib) Global Success and Expansion Q1 2026 Update

24/2/2026
pharma& Announces Health Canada has Accepted for Review the New Drug Submission (NDS) for Rubraca® (rucaparib) in the treatment of Advanced Ovarian Cancer

19/12/2025
U.S. FDA Grants Approval to Rubraca® (rucaparib) for the Treatment of Chemotherapy-Naïve BRCA 1/2-Mutated Metastatic Castration-Resistant Prostate Cancer

15/10/2025
Rubraca® (rucaparib) Accepted by the Scottish Medicines Consortium as a First-Line Maintenance Treatment for Eligible Women with Advanced Ovarian Cancer

2/10/2025
pharma& to Highlight Rubraca® (rucaparib) Five-Year Progression-Free Survival Data in Advanced Ovarian Cancer at ESMO Congress 2025

1/10/2025
pharma& Featured in Business Focus Magazine: Remedy Revivalists

16/7/2025
MHRA Approves pharmaand GmbH’s Pegasys® (peginterferon alfa-2a) as a Treatment for Eligible Patients with the Myeloproliferative Neoplasms (MPNs) Blood Cancers Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

20/6/2025
pharma&’s ATHENA-MONO Clinical Trial Data Suggests That Rubraca® is a Potential Beneficial Therapeutic Option for Patients with HRD-Negative and HRD-Positive Tumors

Read more in our News Archive